Global Blood Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization (accretion) of premium (discount) on marketable securities
Non-cash interest expense
Operating Lease Right Of Use Asset Amortization
Stock-based compensation
Loss from disposal of fixed assets, net

Changes in operating assets and liabilities:
Accounts receivables
Inventories
Prepaid expenses
Other assets, current
Accounts payable
Accrued liabilities
Accrued compensation
Other liabilities, current
Operating lease liabilities
Other liabilities, noncurrent
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Increase in restricted cash
Purchases of other assets
Net cash used in investing activities
Net cash provided by (used in) investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Issuance of Common Stock
Proceeds from issuance of long-term debt, net of debt issuance costs
Proceeds from issuance of common stock in settlement of employee stock purchase plan and exercise of stock options
Repurchases of unvested restricted stock purchases
Taxes paid related to net share settlement of equity awards
Net increase (decrease) in cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Proceeds from issuance of Convertible Notes, net
Purchases of capped call options
Net cash provided by financing activities

Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING INFORMATION:
Accrued issuance costs
Leasehold improvements paid for by landlord
Accrued purchase of property and equipment
RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TO THE CONDENSED CONSOLIDATED BALANCE SHEETS
Cash, cash equivalents
Restricted cash
Total cash and cash equivalents and restricted cash

Comments